November 2014 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
CORRECTION to October 2014 tender notification: in bold and strikethrough
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Ezetimibe 1. | tab 10 mg;30 tablet, blister pack | $34.43 | $3.35 | Ezemibe(Mylan) | 1 June 2015 | 1 August 2015 | 1 November 2015 | Ezetrol( |
|
||||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to listed pharmaceuticals where at least one other brand or pack size is listed no brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) | DVLimit | Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Ezetimibe | tab 10 mg; 30 tablet, blister pack |
$34.43 | $3.35 | Ezemibe (Mylan) |
1% | 1 June 2015 | 1 August 2015 |
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Allopurinol | tab 100 mg; 1,000 tablet, bottle |
$15.90 | $15.11 | Apo-Allopurinol (Apotex) |
1 January 2015 | 1 April 2015 |
| Allopurinol | tab 300 mg; 500 tablet, bottle |
$16.75 | $15.91 | Apo-Allopurinol (Apotex) |
1 January 2015 | 1 April 2015 |
| Permethrin | crm 5%; 30 g OP, plastic tube |
$4.20 | $4.20 | Lyderm (API) |
1 February 2015 | 1 May 2015 |
| Zinc sulphate | cap 137.4 mg (50 mg elemental); 100 capsule, bottle |
$11.00 | $11.00 | Zincaps (Aspen Pharmacare) |
1 January 2015 | 1 April 2015 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to listed pharmaceuticals where only the current brand is listed
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type | Current pack price | New pack price | Hospital Supply Brand (Supplier) | DVLimit | Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Allopurinol | tab 100 mg; 1,000 tablet, bottle |
$15.90 | $15.11 | Apo-Allopurinol (Apotex) |
1% | 1 January 2015 | 1 March 2015 |
| Ephedrine | inj 30 mg per ml,1 ml ampoule; 10 ampoules |
$66.00 | $51.48 | Max Health (Max Health) |
1% | 1 January 2015 | 1 March 2015 |
| Zinc sulphate | cap 137.4 mg (50 mg elemental); 100 capsule, bottle |
$11.00 | $11.00 | Zincaps (Aspen Pharmacare) |
1% | 1 January 2015 | 1 March 2015 |
| Allopurinol | tab 300 mg; 500 tablet, bottle |
$16.75 | $15.91 | Apo-Allopurinol (Apotex) |
1% | 1 January 2015 | 1 March 2015 |
| Permethrin | crm 5%; 30 g, plastic tube |
$4.20 | $4.20 | Lyderm (API) |
1% | 1 February 2015 | 1 April 2015 |
For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.